Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00479128 · ClinicalTrials.gov registry record · Phase 1

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

A Phase 1 study of Solid Tumor and Urethral Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT00479128: Active Phase 1 study of Solid Tumor and Urethral Cancer, sponsored by M.D. Anderson Cancer Center.

NCT00479128 is a Phase 1 study of Solid Tumor and Urethral Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00479128, a Phase 1 study of Solid Tumor and Urethral Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or other solid tumors.

Conditions Studied

Solid Tumor Urethral Cancer

Interventions

  • DRUG Doxorubicin
  • DRUG Gemcitabine
  • DRUG Bortezomib

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2006-09-28
Est. Completion 2026-09-30
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT00479128 still lists

NCT00479128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (64% lower).

The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Doxorubicin is the first listed.

NCT00479128 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00479128 about?

NCT00479128 is a clinical study titled "Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or other solid tumors.

What is the current status of trial NCT00479128?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2006-09-28. Estimated completion is 2026-09-30.

What conditions does trial NCT00479128 study?

This clinical trial studies the following conditions: Solid Tumor, Urethral Cancer.

What interventions are being tested in trial NCT00479128?

The interventions under investigation include: Doxorubicin (DRUG), Gemcitabine (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT00479128?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00479128 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00479128's enrollment target sits among peer trials

80 98th of 196 higher than 98 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00479128, the US trial registry maintained by the National Library of Medicine. NCT00479128 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.